Humana Inc. (HUM)
| Market Cap | 50.96B +51.4% |
| Revenue (ttm) | 154.19B +22.0% |
| Net Income | 1.25B -3.5% |
| EPS | 10.28 -3.7% |
| Shares Out | 120.08M |
| PE Ratio | 41.27 |
| Forward PE | 34.22 |
| Dividend | $3.54 (0.83%) |
| Ex-Dividend Date | Dec 24, 2026 |
| Volume | 783,152 |
| Open | 415.00 |
| Previous Close | 411.79 |
| Day's Range | 411.56 - 444.00 |
| 52-Week Range | 163.11 - 456.50 |
| Beta | 0.64 |
| Analysts | Buy |
| Price Target | 465.13 (+9.61%) |
| Earnings Date | Nov 6, 2026 |
About HUM
Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. The Insurance segment offers individual Medicare Advantage products, including health insurance benefits, including wellness programs, chronic care management, and care coordination; individual Medicare stand-alone prescription drug products (PDP); group Medicare advantage and Medicare stand-alone PDP; Medicare supplements; specialty and ancillary insurance comprising dental, vision, life and disability; and... [Read more]
Financial Performance
In 2025, Humana's revenue was $129.66 billion, an increase of 10.11% compared to the previous year's $117.76 billion. Earnings were $1.19 billion, a decrease of -1.57%.
Financial StatementsAnalyst Summary
According to 26 analysts, the average rating for HUM stock is "Buy." The 12-month stock price target is $465.13, which is an increase of 9.61% from the latest price.
News
Humana Earnings Call Transcript: Q3 2026
2026 adjusted EPS guidance rose to at least $9.50, with individual MA margins on track to double excluding the Stars headwind. Strong BY28 Stars results and early AEP indicators support the recovery, while higher 2027 cost trends remain a key consideration.
Humana Earnings release: Q3 2026
Humana released its Q3 2026 earnings on November 6, 2026, summarizing the period's financial results.
Humana Prepared remarks: Q3 2026
Humana filed a regulatory document on November 6, 2026 disclosing important business information.
Humana Lifts Outlook as Quarterly Revenue Jumps
Humana raised its full-year earnings outlook as consolidated income and revenue rose in the recent quarter.
Humana reports Q3 adjusted EPS (70c), consensus ($1.00)
Reports Q3 revenue $41.16B, consensus $40.89B. “Humana (HUM) is delivering positive results for our members, our patients and their health,” said Humana President and CEO Jim Rechtin. “We are also…
Humana raises FY26 adjusted EPS view to ‘at least’ $9.50 from ‘at least’ $9.00
FY26 consensus $9.16.
Humana Reports Third Quarter 2026 Financial Results; Raises Full Year 2026 Adjusted EPS Guidance
LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) today reported consolidated pretax results and diluted earnings per share for the quarter ended September 30, 2026 (3Q26) versus the quarter e...
Humana Aced Key Medicare Ratings. Earnings Will Spotlight Other Cost Trends.
Costs have been a stumbling block for insurers prior to this year.
Polymarket Odds: Will MRNA, HUM, UAA Beat Earnings Tomorrow?
On Friday, November 6, Moderna ($MRNA), Humana ($HUM), and Under Armour ($UAA) will report their earnings. All three companies will report before the market opens. Traders are already weighing in…
Humana, athenahealth expands electronic prior authorization capabilities
Humana (HUM) and athenahealth announced an expansion of electronic prior authorization capabilities across athenahealth’s nationwide network of more than 180,000 physicians and clinicians. “The collab...
Humana and athenahealth expand electronic prior authorization capabilities nationwide, reducing administrative burden for physicians and helping patients access care faster
BOSTON & LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana and athenahealth today announced an expansion of electronic prior authorization capabilities across athenahealth's nationwide network of more than 180...
Humana Board Declares Payment of Quarterly Dividend to Stockholders
LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) announced today that its Board of Directors has declared a cash dividend to stockholders of $0.885 per share payable on January 29, 2027 to st...
Did Humana Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Humana price target raised to $495 from $468 at Mizuho
Mizuho raised the firm’s price target on Humana (HUM) to $495 from $468 and keeps an Outperform rating on the shares. The firm cites the company “receiving its strong Star…
Humana announces new joint venture with BlackRock
Humana (HUM) announced it has entered into a new joint venture agreement with funds and accounts managed by HPS Investment Partners, a part of BlackRock (BLK), to manage and operate…
Humana Announces New Strategic Joint Venture with BlackRock to Manage CenterWell Senior Primary Care Clinics
LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) today announced it has entered into a new joint venture agreement with funds and accounts managed by HPS Investment Partners, a part of BlackR...
Humana Inc. to Release Third Quarter 2026 Results on November 6, 2026
LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) will release its financial results for the third quarter 2026 (3Q26), as well as prepared management remarks (in PDF format), at 6:00 a.m. Eas...
Humana price target raised to $525 from $475 at Oppenheimer
Oppenheimer raised the firm’s price target on Humana (HUM) to $525 from $475 and keeps an Outperform rating on the shares. Following last week’s favorable Star Ratings release, the firm…
Humana price target raised to $495 from $405 at UBS
UBS raised the firm’s price target on Humana (HUM) to $495 from $405 and keeps a Neutral rating on the shares.
Humana price target raised to $475 from $415 at Truist
Truist analyst David MacDonald raised the firm’s price target on Humana (HUM) to $475 from $415 and keeps a Hold rating on the shares as part of broader research now…
Humana upgraded to Outperform from Market Perform at Raymond James
Raymond James upgraded Humana (HUM) to Outperform from Market Perform with a $520 price target Humana’s increase in 4-star-plus Medicare Advantage membership to 95% for 2027 from 41% in 2026…
Humana Stock (HUM) Soars on Improved Star Ratings, Baird Upgrades to ‘Buy’
Humana ($HUM) stock was up about 12% at the time of writing on Friday after the federal government’s latest data on the health insurer’s Medicare Advantage (MA) plans showed improved…
Friday's First Moves: CRWD & ZS Pirce Target Hikes, HUM Upgrade
Baird is now a bull in Humana (HUM) over greater confidence in the company's 2028 EPS goal. Diane King Hall explains why the note is significant for the rising healthcare company.
Humana Stock Jumps on Raised Medicare Advantage Ratings
Humana shares are soaring after the health insurer said it received improved star ratings for a number of its Medicare Advantage plans.